T1	Participants 624 689	patients with IBS and a study conducted in healthy male subjects.
T2	Participants 786 852	2516 IBS patients with symptoms of abdominal pain and constipation
T3	Participants 862 871	tegaserod
T4	Participants 932 993	In an additional study, 36 healthy male subjects received iv.
T5	Participants 994 1049	single doses of tegaserod (0.8 mg to 20 mg) or placebo.
T6	Participants 1552 1570	healthy volunteers
